scholarly journals Psychosocial interventions in opiate substitution treatment services: does the evidence provide a case for optimism or nihilism?

Addiction ◽  
2017 ◽  
Vol 112 (8) ◽  
pp. 1329-1336 ◽  
Author(s):  
Ed Day ◽  
Luke Mitcheson
Keyword(s):  
Psychosocial Interventions ◽  
Substitution Treatment ◽  
Opiate Substitution Treatment ◽  
Treatment Services

Opiate Substitution Treatment: Poisoned Bodies and the History of Substitution

2013 ◽  
Vol 40 (3) ◽  
pp. 387-413 ◽  
Author(s):  
Ian Walmsley
Keyword(s):  
Substitution Treatment ◽  
Opiate Substitution Treatment ◽  
History Of

Pharmacists’ Role in the Continued Care of Patients under Opiate Substitution Treatment

Therapies ◽  
2013 ◽  
Vol 68 (6) ◽  
pp. 393-400 ◽  
Author(s):  
Nassir Messaadi ◽  
Aymeric Pansu ◽  
Olivier Cohen ◽  
Olivier Cottencin
Keyword(s):  
Substitution Treatment ◽  
Opiate Substitution Treatment

Regaining control: The patient experience of supervised compared with unsupervised consumption in opiate substitution treatment

2013 ◽  
Vol 33 (1) ◽  
pp. 64-70 ◽  
Author(s):  
Caitlin Notley ◽  
Richard Holland ◽  
Vivienne Maskrey ◽  
Jessica Nagar ◽  
Christos Kouimtsidis
Keyword(s):  
Patient Experience ◽  
Substitution Treatment ◽  
Opiate Substitution Treatment

Misuse of Alcohol During Opiate Substitution Treatment

2010 ◽  
Vol 9 (3) ◽  
pp. 99-105
Author(s):  
Charles-Edouard Rengade ◽  
Raymund Schwan
Keyword(s):  
Substitution Treatment ◽  
Opiate Substitution Treatment

Benzodiazepine maintenance in opiate substitution treatment: Good or bad? A retrospective primary care case-note review

2016 ◽  
Vol 31 (1) ◽  
pp. 62-66 ◽  
Author(s):  
Adam Bakker ◽  
Emmanuel Streel
Keyword(s):  
High Risk Group ◽  
Case Note ◽  
Treatment Retention ◽  
Patient Treatment ◽  
Substitution Treatment ◽  
National Guidelines ◽  
Opiate Substitution Treatment ◽  
The Uk ◽  
Treatment Mortality ◽  
Case Note Review

Background: Co-prescribing benzodiazepines to patients in opiate substitution treatment is controversial and often alleged to increase mortality. In an inner-London general practice, patients with problematic benzodiazepine co-dependence were allowed benzodiazepine maintenance treatment (BMT) since 1994, providing an opportunity for analysis. Method: 1) Case-note review of all 278 opiate substitution treatment patients, accruing 1289 patient treatment years; 46% had concurrent BMT. 2) National Health Service database search for patients who died after leaving accrued a further 883 years of information; only patients who left the UK were unaccounted for (4%). Three groups were studied: 1) never obtained benzodiazepine prescription (NOB): n=80); 2) briefly/occasionally prescribed benzodiazepines (BOP): n=71; 3) BMT: n=127. Outcomes measured: Treatment retention (months); deaths/100 patient treatment years; deaths after leaving the service/100 years of information. Results: Treatment retention: NOB: 34 months; BOP: 51 months; BMT: 72 months. In-treatment mortality: NOB: 1.79/100 patient treatment years; BOP: 0.33/100 patient treatment years; BMT: 1.31/100 patient treatment years. Deaths after leaving service: NOB: 2.24/100 years of information, BOP: 0.63/100 years of information. However, mortality for previously BMT-patients increased by 450% to 5.90/100 years of information. Discussion: BMT patients had longer treatment retention than NOB or BOP and lower mortality than NOB patients. It is unlikely that patients had access to prescribed benzodiazepines on leaving the service because of restrictions in the national guidelines but co-dependent patients are a high-risk group who may stand to gain most benefit from opiate substitution treatment if combined with benzodiazepine-maintenance.

An overview of opiate substitution treatment in the European Union and Norway

2002 ◽  
Vol 13 (6) ◽  
pp. 477-484 ◽  
Author(s):  
Ulrik Solberg ◽  
Gregor Burkhart ◽  
Margareta Nilson
Keyword(s):  
European Union ◽  
Substitution Treatment ◽  
The European Union ◽  
Opiate Substitution Treatment

Incidence of hepatitis C in drug injectors: the role of homelessness, opiate substitution treatment, equipment sharing, and community size

2009 ◽  
Vol 137 (9) ◽  
pp. 1255-1265 ◽  
Author(s):  
N. CRAINE ◽  
M. HICKMAN ◽  
J. V. PARRY ◽  
J. SMITH ◽  
A. M. WALKER ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Substitution Treatment ◽  
Switching Regression ◽  
Community Size ◽  
Opiate Substitution Treatment ◽  
South Wales ◽  
Drug Injectors ◽  
Treatment Equipment ◽  
Incident Rate

SUMMARYA prospective cohort study estimated the incidence of hepatitis C virus (HCV) in drug injectors in South Wales (UK). In total, 286/481 eligible seronegative individuals were followed up after approximately 12 months. Dried blood spot samples were collected and tested for anti-HCV antibody and behavioural data were collected at baseline and follow-up. HCV incidence was 5·9/100 person-years [95% confidence interval (CI) 3·4–9·5]. HCV incidence was predicted by community size [incident rate ratio (IRR) 6·6, 95% CI 2·11–20·51,P=0·001], homelessness (IRR 2·9, 95% CI 1·02–8·28,P=0·047) and sharing injecting equipment (IRR 12·7, 95% CI 1·62–99·6,P=0·015). HCV incidence was reduced in individuals in opiate substitution treatment (IRR 0·34, 95% CI 0·12–0·99,P=0·047). In order to reduce follow-up bias we used multiple imputation of missing data using switching regression; after imputation estimated HCV incidence was 8·5/100 person-years (95% CI 5·4–12·7). HCV incidence varies with community size, equipment sharing and homelessness are associated with increased HCV incidence and opiate substitution treatment may be protective against HCV.

Sign in / Sign up

Export Citation Format

Share Document